Register of
Medicinal Products

Product class: Medicinal product with marketing authorization
Medicinal product class: Veterinary medicine
Name of medicinal product: Cryptisel
Active substances:
Halofuginone
Estonian, English, Latin
ATC code: QP51BX01
Dosage form: oral solution
Strength: 0,5mg 1ml
Legal status for supply*: Subject to medicinal prescription
Summary of product characteristics (SPC):  (last updated March 31, 2023)
Package information leaflet (PIL): EST  (last updated November 2, 2020)
Labelling:  (last updated November 2, 2020)
Indication: Prevention of diarrhoea due to diagnosed Cryptosporidium parvum, in farms with history of cryptosporidiosis. Administration should start in the first 24 to 48 hours of age. Reduction of diarrhoea due to diagnosed Cryptosporidium parvum. Administration should start within 24 hours after the onset of diarrhoea. In both cases, the reduction of oocysts excretion has been demonstrated.
Safety features: No
Marketing authorization holder: Livisto Int'l S.L. 
Marketing authorization number: 2258 
Marketing authorization issued on: November 2, 2020 
Marketing authorization expires on: November 2, 2025 
Marketing authorization procedure type: Decentralised 
Assessment report:   
Package code Name of medicinal product Dosage form Package Legal status Reimbursements Reference price Last imported PƤritolumaa Additional information
1804452  Cryptisel  oral solution  0,5mg 1ml 290ml 1TK  Prescription           
1804463  Cryptisel  oral solution  0,5mg 1ml 490ml 1TK  Prescription      02.02.2024     
1804474  Cryptisel  oral solution  0,5mg 1ml 980ml 1TK  Prescription           
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere